To our knowledge, this is the first study to simulate the expected overall survival and determine the most effective personalized management strategies for carriers BRCA1 and BRCA2 variants who underwent BCT for unilateral early-stage breast cancer taking into account the type of the pathogenic variant (BRCA1 or BRCA2), age at primary breast cancer diagnosis, breast cancer subtype, stage, and received systemic treatment. This evidence concerns the gene BRCA2 and breast cancer.